Medical Necessity of Vyepti 300mg IV for Chronic Migraine

Patient Profile and Treatment History

A 43-year-old female with chronic migraine without aura is experiencing 8-12 migraines per month, indicating partial but inadequate response to current 100mg Vyepti dosing, and has previously tried multiple preventive and abortive medications, including anti-CGRP medications, anticonvulsants, NSAIDs, triptans, and muscle relaxants, as recommended by the American Academy of Neurology 1, 2, 3, 4

The patient meets ICHD-3 criteria for chronic migraine, with ≥15 headache days per month for >3 months, and meets criteria for migraine without aura on ≥8 days per month, as defined by the International Headache Society 1, 2
The American Headache Society recommends a treatment algorithm that includes first-line preventive treatments, such as topiramate and beta-blockers, second-line treatments, such as Botox, and third-line treatments, such as Vyepti, with dose escalation to 300mg considered medically necessary for patients with partial response to 100mg and significant remaining disease burden 3, 4

Clinical trials have demonstrated that the 300mg dose of Vyepti shows greater efficacy than the 100mg dose in reducing monthly migraine days, with a greater reduction in monthly migraine days (-4.3 vs -3.9 days) and a higher percentage of patients achieving ≥50% reduction in monthly migraine days (56.3% vs 49.8%), as reported by the American Academy of Neurology 3
The patient's significant remaining disease burden (8-12 migraines/month) and documented partial response to 100mg support the medical necessity of increasing Vyepti to 300mg IV every 3 months, as recommended by the American Headache Society 3, 4

Chronic migraine significantly impairs quality of life and daily functioning, and reducing migraine frequency and severity directly improves quality of life and reduces disability, as reported by the American Academy of Neurology 5, 6

The American Academy of Neurology recommends considering dose escalation for patients with chronic migraine who have demonstrated a partial response to initial treatment, as seen in patients who have failed oral preventives such as topiramate, propranolol, depakote, and nortriptyline 7
Patients who have failed CGRP antagonists and are currently receiving Botox may also benefit from dose escalation, as evidenced by the patient's complex medical situation and partial response to 100mg 7

The FDA label supports dose escalation to 300mg for patients who have demonstrated a partial response to 100mg, with no increased risk of adverse events or serious adverse events 7